跳转到主内容

非常抱歉，我们不完全支持您的浏览器。如果您可以选择，请升级到较新版本或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更高版本。如果您无法进行此操作且需要支持，请将您的反馈发送给我们。

全新设计的官网为您带来全新体验，期待您的反馈 在新的选项卡/窗口中打开

Elsevier
通过我们出版

Cancer Research UK

Elsevier has confirmed with Cancer Research UK 在新的选项卡/窗口中打开 how authors publishing in Elsevier journals can comply with their open access policy. 在新的选项卡/窗口中打开 Details of how to comply are outlined below.

Policies

Cancer Research UK requires electronic copies of any research articles that have been accepted for publication in a peer-reviewed journal to be made available through Europe PubMed Central (Europe PMC) as soon as possible, and no later than six months, after final publication.

Authors can comply by publishing gold open access in either an Elsevier open access or hybrid journal after paying an APC, or by publishing subscription and using the green open access route in any journal which allows authors to self-archive their accepted manuscripts in Europe PMC after an embargo period of no more than six months. Articles accepted for final publication on or after 1 January 2022 will be required to be made openly-available in Europe PMC immediately on publication.

Authors can choose to publish gold open access in Elsevier’s open access or hybrid journals. This includes journals published by The Lancet. When publishing open access, the corresponding author will be given a choice of two Creative Commons licenses. Cancer Research UK policy states that authors are required to select a Creative Commons Attribution (CC BY) 4.0 license.

An article publication charge (APC) is required to be paid in order to make an article open access. Elsevier's APCs range between circa US $150 and c$9,900, excluding tax, and are journal specific. Please refer to the guide for authors on the journal homepage for more information.

Cancer Research UK provides designated funds to support the payment of APCs through block grants to institutions. Authors should apply to their host institutions to access these funds.

Upon final publication, Elsevier will immediately send to Europe PMC the final published journal article (PJA) as it appears on ScienceDirect. Europe PMC should link back to the final version of the article hosted on ScienceDirect, via its DOI, so that the article can be cited.

Cancer Research UK-funded authors who do not have funds available for gold open access can self-archive their accepted manuscript on Europe PMC after the embargo period for their specific journal has expired. Accepted manuscripts must include a link back to the final published article on ScienceDirect. Please see our sharing policy for more information.

Help and support